Introduction
Hematopoietic stem cells (HSCs) maintain a balance between self-renewal and differentiation to replenish all blood cell types. HSC regulation requires both intrinsic and extrinsic signals.
Cytokines, chemokines, adhesion molecules, proteolytic enzymes, and neurotransmitters are produced by environmental niches function together to regulate HSC function and fate [1] [2] [3] .
Prostaglandin E2 (PGE2) is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGESs) 4 . PGE2 modulates various pathological and physiological activities, such as cancer, fever, inflammation, atherosclerosis, blood pressure, stroke, and reproduction, as recently reviewed by Legler et al. 5 . PGE2 also modulates hematopoiesis [6] [7] [8] [9] [10] [11] [12] [13] [14] . PGE2 is involved in the production of definitive HSCs in the aorta-gonad-mesonephros region and in HSC engraftment 15 . PGE2 enhances HSC homing, survival, and proliferation 16 . More recently, a stable derivative of PEG, 16, 16-dimethyl PGE2 (dmPGE2), was shown to significantly enhance the engraftment of human cord blood cells in a xenotransplantation model 17 .
Although PGE2 could be used in a clinical setting to improve hematopoietic transplantation therapy, the expression profiles of its four receptors (EP1, EP2, EP3, and EP4) vary within different organs and tissues 18 . EP signaling pathways differ according to EP EP4, an activation of EP1 regulates Ca 2+ channel gating via an unidentified G protein 21 . The activation of EP3 inhibits adenylate cyclase via Gi and decreases cAMP levels 18 . A recent study demonstrated that crosstalk between the PGE2 and Wnt signaling at the level of β-catenin stabilization in hematopoietic stem/progenitor cells (HSPCs), which contributes to the regulation of HSPC development and regeneration 22 . This suggests that the increase in cAMP concentrations and GSK3β phosphorylation via EP2 or EP4 signaling are key events during PGE2-mediated HSC regulation. However, it is not completely clear whether EP2 or EP4 is primarily responsible for the regulation of adult HSCs.
PGE2 also affects the bone marrow (BM) microenvironment 23, 24 . When mice were continuously administered PGE2, they exhibited less bone trabeculae and more short-term HSCs (ST-HSCs) and multipotent progenitors (MPPs) 24 . Although it was suggested that these effects are due to enlargement of the physical space in the BM, PGE2 may also stimulate a non-hematopoietic cell population to indirectly regulate HSPCs.
Here, we analyzed the ability of PGE2 signaling to directly regulate HSPCs, and also studied the indirect regulation of HSPC activity by PGE2 via stimulation of a non-hematopoietic cell population. We found that PGE2 signaling positively regulates HSCs both directly and via activation of a non-hematopoietic cell population, and that EP4 is a major receptor for the PGE2-mediated regulation of HSPCs.
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Methods

Mice
C57BL/6 mice were purchased from Japan SLC. C57BL/6 mice congenic for the Ly5 locus (B6-Ly5.1) were purchased from Sankyo-Lab Service. Since EP4 knockout (KO) mice do not survive on a C57BL/6 background 25,26 , they were maintained on a mixed background of 129/Ola × C57BL/6. Animals were cared for in accordance with the guidelines of the Keio University
School of Medicine for Animal and Recombinant DNA experiments. All animal experiments were approved by the ethical review board of the Keio University School of Medicine.
Antibodies
Antibodies used for FACS analyses and immunoblotting are listed in the supplemental data.
Reagents
PGE2 was purchased from Sigma Aldrich. dmPGE2 was purchased from Enzo Life Sciences.
The EP1-selective agonist (ONO-DI-004: 17S,17,20-dimethyl-2,5-ethano-6-oxo-PGE 1 ), the EP2-selective agonist (16s-9-deoxy-9β-chloro-15-deoxy-16-hydroxy-17,17-propano-19,20-didehydro-PGE2), the EP3-selective agonist (ONO-AE-248: 11,15-O-dimethyl-PGE2), and the EP4-selective agonist (16-(3-methoxymethyl) phenyl-omega-tetranor-3,7-dithia prostaglandin E 1 ) were provided by Ono Pharmaceutical Co., Ltd.
Cell preparation and sorting
The preparation of BM cells and immunostaining for flow cytometry have been described 27 . The isolation of endosteal cell populations on the bone surface has been described 28 . Stained cells were analyzed and sorted using a FACSvantage DiVa flow cytometer (BD Biosciences) and FACSAria (BD Biosciences).
Quantitative RT-PCR (Q-PCR) analyses
Methods for conventional Q-PCR, Digital PCR (Digital Array™, Fluidigm), and Q-PCR array (Dynamic Array™, Fluidigm) analyses are described in the Supplemental Data.
Colony assay
To were cocultured on each endosteal population for three days in MyeloCult® (StemCell Technologies) without cytokines. Cells were then collected for the colony assay.
Immunoblot analysis
To evaluate the effects of treatments on the levels of phosphorylated GSK3β, non-phosphorylated GSK3β, and phosphorylated β-catenin in HSPCs, BM Lin -c-Kit + cells were treated with dmPGE2 (10 μM), EP4 agonist (10 or 100 μM), or EP2 agonist (10 or 100 μM) in 2% FCS/PBS for 30 min at room temperature. Cells were lysed and subjected to SDS-PAGE and immunoblotting using antibodies against phospho-GSK3β (Ser9) (D85E12, Cell Signaling)
(1:1000), non-phosphorylated GSK3β (27C10, Cell Signaling) (1:1000), or phosphorylated β-catenin (Ser675) (D2F1, Cell Signaling) (1:100). To assess downstream signaling, BM Lin -c-Kit + cells were treated with dmPGE2 (10 μM), EP4 agonist (100 μM) or EP2 agonist (100 μM) in the presence of PKA (10 μM H89, Sigma Aldrich) or PI3K (10 μM LY294002, Sigma Aldrich) inhibitors in 2% FCS/PBS for 30 min at room temperature. Densitometric quantification was performed on scanned immunoblot images using Multi Gauge V3.1 (Fuji Film).
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From EP4 shRNA sequences and preparation of shEP4 retrovirus EP4 shRNA sequences were as follows: shEP4-1, 5′-CGAGTGTTCATTAACCAGTTA-3′ and shEP4-2, 5′-CCACCTCGCTGAGAACTTT-3′. The sequence was separated by a nine nucleotide non-complementary spacer (TTCAAGAGA) from the corresponding reverse complement of the same 21 nucleotide sequence. A scrambled sequence (5′-GTCCCTATCGCCATTTACT-3′) served as a control. Oligonucleotides were cloned into BglII and HindII sites of the pReGS retrovirus vector provided by Dr. Hara (The Tokyo Metropolitan Institute of Medical Science). Retrovirus-shEP4 was produced using the PlatE cell line.
Retroviral transduction
LSK cells were pre-cultured for one day, transfected with retrovirus-shEP4 on RetroNectin® (Takara Bio) using Magnetofection™ (OZ Biosciences), and incubated for a further two days at 37 ºC in 5% CO 2 . Cells were maintained in SF-O3 medium containing 1.0% BSA, 100 ng/ml stem cell factor, 100 ng/ml thrombopoietin, and 10 -5 M 2-mercaptoethanol.
BM reconstitution assay
Donor cells were transplanted into lethally-irradiated recipient mice. Peripheral blood (PB) chimerism was analyzed every month. The percentage of donor-derived cells in BM and the ability of donor-derived cells to differentiate into various cell types were analyzed 3-4 months after BMT. Details of the BM reconstitution assay are described in the Supplemental Data. 
Results
Expression of EP receptors in HSPCs
To determine the expression of EP receptors in fractionated mouse BM cells we undertook Q-PCR analysis ( Figure 1A) Figure S1 ). This data suggests that all endosteal cell populations contribute to PGE2 production to varying extents.
PGE2/EP4 signaling functions in HSPC differentiation and LTR capacity
Next, we examined EP4 KO mice to analyze the role of EP4 in PGE signaling in hematopoiesis.
Although PB counts were normal, analysis of T, B, and myeloid cells in PB revealed that EP4 KO mice exhibited a slightly higher percentage of T cells (47.7 ± 5.0% in WT and 55.1 ± 6.5% 
EP2 KO mice exhibit normal hematopoietic activity
We next evaluated EP2 receptor function in HSPC regulation by analyzing EP2 KO mice. These mice had normal PB cell counts and a normal differentiation capacity (Supplemental Figure   S3A and Supplemental Table S2 Figure S3C ).
When the LTR capacity of EP2 KO LSK and LSKCD34 -cells was analyzed, no defect in BM reconstitution was detected. (Supplemental Figure S3D ). Short-term treatment with an EP2 agonist did not change the number of CFU-Cs and HPP-CFCs, suggesting that the colony-forming activity of LSK cells was unaffected (Supplemental Figure S4 ). These data suggest that PGE2/EP2 signaling does not affect the self-renewal activity or proliferation activity of HSPCs.
EP4 stimulation increases HSPC colony formation and LTR capacity
To evaluate the role of PGE2 signaling through EP4 in HSPCs, we assessed the effect of the EP4 agonist on HSPC colony formation activity. When LSK cells were briefly treated with dmPGE2 or the EP4 agonist and cultured in methylcellulose medium, the number of CFU-Cs increased relative to the control ( Figure 3A ). In addition, dmPGE2 and EP4 agonist treatments increased the number of HPP-CFCs ( Figure 3B ). A high dose (100 μM) of dmPGE2 was less effective for HPP-CFC formation compared to the 0.1, 1, or 10 μM of dmPGE2. This was not the case for the EP4 agonist.
Next, we examined the effect of the EP4 agonist on the LTR capacity of LSK cells. LSK cells were treated with dmPGE2 (10 μM), EP4 agonist (10 or 100 μM) for two hours on ice and transplanted into recipient mice. In the PB, 10 μM dmPGE2-and 100 μM EP4 agonist-treated cells showed higher chimerism of donor-derived cells than the control cells four months after BMT, while there was no statistically significant difference in the frequency of donor-derived cells between controls and 10 μM EP4 agonist-treated cells ( Figure 3C ). On the other hand, in comparison to control cells, 10 μM dmPGE2 and EP4 agonist (10 or 100 μM)-treated cells showed greater engraftment in BM MNCs ( Figure 3D ) and in the LSK fraction ( Figure 3E ) four months after BMT. These results indicate that PGE2/EP4 signaling positively affects the engraftment of hematopoietic cells.
PGE2 signaling through EP4 induces phosphorylation of GSK3β and β-catenin in HSPCs
Next, we evaluated the function of PGE2/EP4 signaling in the stabilization of β-catenin in HSPC. PGE2 signaling reportedly interacts with the Wnt/β-catenin pathway 22 . GSK3β is a component of the β-catenin destruction complex and its phosphorylation at Ser9 decreases its ability to associate with other complex members. GSK3β phosphorylation was monitored in For
Discussion
PGE2 signaling interacts with the Wnt/β-catenin pathway and contributes to the generation and regenerative capacity of HSPCs 22 . Here, we demonstrated that the EP4 receptor plays a crucial role in the direct regulation of HSPCs by PGE2 signaling. We also found that PGE2/EP4 signaling supports hematopoiesis indirectly by stimulating a specialized population of cells in
MPCs.
Direct function of PGE2 in the regulation of adult HSPCs
EP2 and EP4 receptors stimulate Gs protein, which leads to cAMP production and activation of the cAMP/PKA pathway 18 , and modulation of Wnt/β-catenin signaling 22 . Digital PCR analysis clearly demonstrated that HSPCs had a higher copy number of EP4 than that of EP2 (Figure 1 ), and EP2 KO mice did not have defects in the number of HSPCs. EP2-deficient HSPCs showed normal colony formation and LTR capacities (Supplemental Figure S3 ). In addition, we found that EP2 agonist treatment did not affect the colony formation of LSK cells (Supplemental Figure S4 ). In contrast, EP4 KD reduced BM reconstitution (Figure 2) , and both EP4 KO mice and recipient mice transplanted with EP4 KD LSK cells had increased percentages of T and myeloid cells and decreased percentages of B cells (Figure 2 and Supplemental Figure S2 ).
These findings suggest that EP4, but not EP2, affects the PGE2-mediated direct regulation of adult HSCs. Furthermore, the EP4 agonist increased the colony-forming capacity and LTR capacity of LSK cells (Figure 3 ). Further investigations using for instance the serial BMT assay will be necessary to elucidate whether PGE2/EP4 signaling enhances the self-renewal activity of LT-HSCs.
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We found that EP4 agonist induced phosphorylation of GSK3β (Ser9) and β-catenin (S675). A PKA inhibitor significantly decreased PGE2-and EP4 agonist-induced phosphorylation of GSK3β, while a PI3K inhibitor did not (Figure 4 ). These data suggest that PKA is the main downstream effector of PGE2/EP4 signaling that is responsible for activating β-catenin in HSPCs.
Wnt/β-catenin pathway is required for the development of leukemia stem cells in acute myeloid leukemia (AML) 39 . In colon cancer, PGE2/EP2 signaling interacts with the Wnt/β-catenin pathway through PI3K/Akt to promote cancer cell growth 40 . Therefore, it would be interesting to determine whether PGE2/EP4 signaling functions to activate Wnt/β-catenin signaling during AML development.
Function of PGE2 in HSPC regulation mediated by MPCs
We identified that PGE2 also indirectly regulated HSPCs by modulating ALCAM -Sca-1 + MPCs. also activated ALCAM -Sca-1 + MPCs, whereas the other EP agonists had no effect. These data suggest that the activation of ALCAM -Sca-1 + MPCs by dmPGE2 requires EP4. However, the effects of the EP4 agonist on HPP-CFC formation and gene expression were less potent than
LSK cells co-cultured with dmPGE2-treated ALCAM
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Macrophages and monocytes have strong PGE2 biosynthetic capacity 7, 41, 42 . In this study, we found that ALCAM -Sca-1 + MPCs expressed high levels of Ptges1 and Cox2 (Supplemental Figure S1 ), which participate in PGE2 synthesis under proinflammatory conditions. The expression of Ptges1, Pteges2, Cox1 and Cox2 was upregulated in ALCAM -Sca-1 + MPCs after 5-FU treatment (Supplemental Fig. S8 ). Therefore, we anticipate that MPCs facilitate the recovery of HSPCs under myelosuppressive conditions by producing PGE2. Autocrine PGE2 activity also activates MPCs and supports HSPC recovery. Representative data from three independent experiments are shown. 
PGE2 signaling functions in HSPC recovery after myelosuppression
